Novavax shares tumbled after it slashed its full-year revenue forecast by half due to tepid demand for its Covid-19 jab, underlining the challenges faced by vaccine makers that came late to market with their pandemic-related shots.
由于对Covid-19疫苗的需求不振，诺瓦瓦克斯公司将其全年收入预期削减了一半，股价暴跌，突显出疫苗制造商在推出与大流行相关的疫苗后面临的挑战。
您已阅读8%（303字），剩余92%（3331字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。